🎙 Biotech Blueprint is officially a podcast!
We cover biotech research, innovation, strategy, and market dynamics with expert guests from industry and academia. You’ll find both short This Week in Biotech video recaps and long-form podcast interviews below.
In this week’s episode, I break down the biggest stories shaping the biotech and pharma landscape from May 30 to June 7, 2025.
🔬 ASCO 2025 delivered big results in oncology, with AstraZeneca’s camizestrant, Summit’s ivonescimab, and Gilead/Merck’s TROP-2 ADC combo showing major clinical gains.
💰 Strategic dealmaking followed the data, including a $1.5B BioNTech/Bristol Myers deal and Sanofi’s $9.1B Blueprint Medicines acquisition.
💊 Regeneron staked a claim in obesity, pushing beyond GLP-1s with a muscle-sparing antibody combo and a dual agonist licensing deal.
🧬 Gene therapy remains scientifically strong but commercially uncertain-Regenxbio soared in the clinic but dipped on Wall Street.
📈 Markets showed a cautious rebound, with XBI and IBB edging up and Omada Health making a strong IPO debut under ticker OMDA.
We also spotlight clinical standouts from Moderna and more.
If you enjoy this content, subscribe to the newsletter below.
Thanks for tuning in. I’ll be back next week with more biotech news you need to know.
DISCLAIMER: This content is for informational purposes only. It should not be taken as legal, tax, investment, financial, or other advice. The views expressed here are my own and do not reflect the opinions of any company or institution.
DISCLOSURE: I have no business relationships with any company mentioned in this article.
Share this post